---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-008491"
form_type: "8-K"
ticker: "HIND"
cik: "0001427570"
company_name: "Vyome Holdings, Inc"
filed_at: "2024-05-20T23:59:59+00:00"
generated_at: "2026-06-01T12:30:15.638190+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# ReShape Lifesciences Q1 rev $1.9M (-15% YoY), gross margin up to 59.9%, opex down 51%

## Summary
- Q1 revenue $1.9M, down 15% YoY; gross margin improved to 59.9% (from 53.5%) due to lower overhead.
- Total operating expenses down 51% YoY; sales & marketing down 53%, G&A down 56%.
- Cost reduction plan expected to cut 2024 opex by ~55% vs 2023; RIF implemented.
- Cash and equivalents $2.5M; net working capital $4.4M.
- Lap-Band 2.0 FLEX launch underway; intragastric balloon patent issued; M&A search with Maxim Group.

## SEC filing metadata
- accession: 0001558370-24-008491
- form_type: 8-K
- ticker: HIND
- cik: 0001427570
- company_name: Vyome Holdings, Inc
- filed_at: 2024-05-20T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1427570/000155837024008491/0001558370-24-008491-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1427570/000155837024008491/rsls-20240515x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-008491
- JSON: https://secwatch.observer/filing/0001558370-24-008491.json
- Plain text: https://secwatch.observer/filing/0001558370-24-008491.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.